Barrier Cleared to Launch Dermatitis Gel
Posted on: Monday, 31 July 2006, 09:00 CDT
Barrier Therapeutics has received FDA approval for Xolegel gel for the topical treatment of seborrheic dermatitis in immunocompetent adults and children 12 years of age and older.
Xolegel (ketoconazole, USP), previously referred to as Sebazole, is a topical formulation of 2% ketoconazole, an antifungal agent, in a waterless gel for once-daily application. Xolegel is the first prescription gel formulation of ketoconazole approved in the US.
Seborrheic dermatitis affects approximately 8.5 million people in the US. Until the approval of Xolegel, current prescription therapies have consisted primarily of shampoos, topical antifungal creams including ketoconazole creams, and topical steroids. These treatments typically require two or more applications per day over periods of up to four weeks to be effective. With its unique gel formulation, Xolegel provides patients with a dosing regimen of a once-daily application for two weeks, requiring approximately 75% fewer applications compared to some traditional therapies.
Xolegel is Barrier's second product to be approved by the FDA this year and will become the company's third marketed product in the US. Barrier expects to launch the product during the fourth quarter of 2006.
Source: Datamonitor
Related Articles
- Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
- US Farms, Inc. Launches New Aloe Vera Skin Gel Product
- Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
- Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
- Global Warming Expected to Spike Pollen and Spring Allergies - New Drug-Free Topical Gels Boost Hope for Allergy Sufferers
- Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference
- XOMA Begins Phase 2a Clinical Trial to Evaluate XOMA 629 Topical Gel As a Treatment for the Common Skin Disease, Impetigo
- Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing By FDA for the Treatment of Overactive Bladder
- Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
- Dow Pharmaceutical Sciences Announces FDA Approval of METROGEL(R) (Metronidazole) Topical Gel 1% for Rosacea
 |
 |
User Comments (0)
RSS Feeds